StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note published on Saturday morning. The firm issued a sell rating on the stock.

Bio-Path Trading Down 9.7 %

Shares of NASDAQ:BPTH opened at $0.81 on Friday. The business’s 50 day moving average price is $0.98 and its 200-day moving average price is $1.58. Bio-Path has a 1 year low of $0.80 and a 1 year high of $12.40.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the company earned ($10.60) EPS. Research analysts predict that Bio-Path will post -6.2 EPS for the current year.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.